Journal of Cystic Fibrosis
Volume 9, Issue 4 , Pages 263-268 , July 2010

Renal impairment in children with cystic fibrosis

  • Annick Andrieux

      Affiliations

    • CHU de Bordeaux, Centre de Ressources et de Compétences de la Mucoviscidose pédiatrique, Hôpital Pellegrin Enfants, Bordeaux, France
    • ,
  • Jérôme Harambat

      Affiliations

    • CHU de Bordeaux, Centre de Référence Maladies Rénales Rares (SORARE), Hôpital Pellegrin, Bordeaux, France
    • ,
  • Stéphanie Bui

      Affiliations

    • CHU de Bordeaux, Centre de Ressources et de Compétences de la Mucoviscidose pédiatrique, Hôpital Pellegrin Enfants, Bordeaux, France
    • ,
  • Fabienne Nacka

      Affiliations

    • Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique plurithématique, CHU de Bordeaux, France
    • ,
  • Albert Iron

      Affiliations

    • CHU de Bordeaux, Centre de Ressources et de Compétences de la Mucoviscidose pédiatrique, Hôpital Pellegrin Enfants, Bordeaux, France
    • ,
  • Brigitte Llanas

      Affiliations

    • CHU de Bordeaux, Centre de Référence Maladies Rénales Rares (SORARE), Hôpital Pellegrin, Bordeaux, France
    • ,
  • Michael Fayon

      Affiliations

    • CHU de Bordeaux, Centre de Ressources et de Compétences de la Mucoviscidose pédiatrique, Hôpital Pellegrin Enfants, Bordeaux, France
    • Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique plurithématique, CHU de Bordeaux, France
    • Corresponding Author InformationCorresponding author. Service de Pédiatrie, Unité de Pneumologie Pédiatrique, Hôpital Pellegrin Enfants, Place Amélie Raba-Léon, 33076 Bordeaux, France. Tel.: +33 5 5679; fax: +33 5 56795658.

Received 20 October 2009 ,Revised 6 March 2010 ,Accepted 11 March 2010.

References 

  1. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970–1989. Am J Epidemiol. 1996;143:1007–1017
  2. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947–2003. Eur Respir J. 2007;29:522–526
  3. Hodson ME, Simmonds NJ, Warwick WJ, et al. An international/multicentre report on patients with cystic fibrosis (CF) over the age of 40years. J Cyst Fibros. 2008;7:537–542
  4. Soulsby N, Greville H, Coulthard K, Doecke C. Renal dysfunction in cystic fibrosis: is there cause for concern?. Pediatr Pulmonol. 2009;44:947–953
  5. Hoppe B, Hesse A, Bromme S, Rietschel E, Michalk D. Urinary excretion substances in patients with cystic fibrosis: risk of urolithiasis?. Pediatr Nephrol. 1998;12:275–279
  6. Terribile M, Capuano M, Cangiano G, et al. Factors increasing the risk for stone formation in adult patients with cystic fibrosis. Nephrol Dial Transplant. 2006;21:1870–1875
  7. Hoppe B, von Unruh GE, Blank G, et al. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis. Am J Kidney Dis. 2005;46:440–445
  8. Tan KH, Mulheran M, Knox AJ, Smyth AR. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med. 2003;167:819–823
  9. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol. 2005;39:15–20
  10. Stephens SE, Rigden SP. Cystic fibrosis and renal disease. Paediatr Respir Rev. 2002;3:135–138
  11. Schwarzenberg SJ, Thomas W, Olsen TW, et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care. 2007;30:1056–1061
  12. Quattrucci S, Rolla M, Cimino G, et al. Lung transplantation for cystic fibrosis: 6-year follow-up. J Cyst Fibros. 2005;4:107–114
  13. Bech B, Pressler T, Iversen M, et al. Long-term outcome of lung transplantation for cystic fibrosis—Danish results. Eur J Cardiothorac Surg. 2004;26:1180–1186
  14. Castellani C, Cuppens H, Macek M, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros. 2008;7(3):179–196
  15. Cade A, Walters MP, McGinley N, et al. Evaluation of fecal pancreatic elastase-1 as measure of pancreatic exocrine function in children with cystic ficrosis. Pediatr Pulmonol. 2000;29:172–176
  16. Lamireau T, Monnereau S, Martin S, Marcotte JE, Winnock M, Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol. 2004;41:920–925
  17. Nash KL, Allison ME, McKeon D, et al. A single centre experience of liver disease in adults with cystic fibrosis 1995–2006. J Cyst Fibros. 2008;7:252–257
  18. Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976;58:259–263
  19. Collard L. Normal values. In:  Cochat P editors. European Society for Paediatric Nephrology (ESPN) Handbook. Lyon: Medcom; 2002;p. 453–466
  20. Matos V, van Melle G, Boulat O, Markert M, Bachmann C, Guignard JP. Urinary phosphate/creatinine, calcium/creatinine, and magnesium/creatinine ratios in a healthy pediatric population. J Pediatr. 1997;131:252–257
  21. Prigent A. Monitoring renal function and limitations of renal function tests. Semin Nucl Med. 2008;38:32–46
  22. McDiarmid SV, Ettenger RB, Hawkins RA, et al. The impairment of true glomerular filtration rate in long-term cyclosporine-treated pediatric allograft recipients. Transplantation. 1990;49:81–85
  23. Hellerstein S, Berenbom M, DiMaggio S, Erwin P, Simon SD, Wilson N. Comparison of two formulae for estimation of glomerular filtration rate in children. Pediatr Nephrol. 2004;19:780–784
  24. Bronsveld I, Conemans LH, Van de Graaf EA, Lammers JW, Teding van Berkhout F. Creatinine clearance in cystic fibrosis patients: MDRD, Cockcroft–Gault and measured creatinine clearance. J Cyst Fibros. 2009;8:Suppl 2:S107
  25. Edwards CT, West N. Estimating renal function in paediatric cystic fibrosis patients. J Cyst Fibros. 2009;8:Suppl 2:S108
  26. Dobson L, Stride A, Bingham C, Elworthy S, Sheldon CD, Hattersley AT. Microalbuminuria as a screening tool in cystic fibrosis-related diabetes. Pediatr Pulmonol. 2005;39:103–107
  27. Abramowsky CR, Swinehart GL. The nephropathy of cystic fibrosis: a human model of chronic nephrotoxicity. Hum Pathol. 1982;13:934–939
  28. Gibney EM, Goldfarb DS. The association of nephrolithiasis with cystic fibrosis. Am J Kidney Dis. 2003;42:1–11
  29. Böhles H, Gebhardt B, Beeg T, Sewell AC, Solem E, Posselt G. Antibiotic treatment-induced tubular dysfunction as a risk factor for renal stone formation in cystic fibrosis. J Pediatr. 2002;140:103–109
  30. Williams HE, Wandzilak TR. Oxalate synthesis, transport and the hyperoxaluric syndromes. J Urol. 1989;141:742–749
  31. Sidhu H, Hoppe B, Hesse A, et al. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet. 1998;352:1026–1029
  32. Bentur L, Kerem E, Couper R, et al. Renal calcium handling in cystic fibrosis: lack of evidence for a primary renal defect. J Pediatr. 1990;116:556–560

☆ Part of the data reported here has been presented at the annual meeting of the 32nd European Cystic Fibrosis Conference, 10–13rd June 2009, Brest, France, and printed in abstract form (J Cyst Fibros 8: S111, 2009).

PII: S1569-1993(10)00033-0

doi: 10.1016/j.jcf.2010.03.006

Journal of Cystic Fibrosis
Volume 9, Issue 4 , Pages 263-268 , July 2010

Article Tools

* Image Usage & Resolution